FDA Investigator Charles Yuanchia Kuo, PhD
Charles Yuanchia Kuo, PhD has inspections in 1 countries as of 27 Jul 2023. Charles Yuanchia Kuo, PhD has collaborated with a combined 1422 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
4
Last Inspection Date:
27 Jul 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Country:
United States of America
Co-Investigator(s):
Aditi S Thakur,
Alberto A Viciedo,
Alice C Silva,
Andrew "Drew" Haack, PhD,
Andrew Haack, PhD,
Andrew K Haack, PhD,
Anita Narula, PhD,
Arie C Menachem,
Barbara Janine Breithaupt,
Brian Janelsins, PhD,
Byungja E Marciante,
CDR Donald Ertel,
Chava Kimchi Sarfaty, PhD,
Christopher R Czajka,
Dawn L Wydner,
Deborah M Trout,
Edmund F Mrak, Jr,
Ellen P Madigan,
Erik W Koester,
Guerlain Ulysse,
Haley H Seymour,
Harperd,
Janet L Bowen,
Jie He,
Joan Johnson,
John P Mistler,
Jose O Hernandez,
Jose Ohernandez Guzman,
Justin A Boyd,
Kathleen M Jordan,
Kathryn E King,
Ko U Min,
LCDR Debra Emerson,
Leiyun Boone, PhD,
Lisa K Capron,
Marlene G Swider,
Mary Jeanet Mcgarry,
Megan A Haggerty,
Michael P Anthony,
Michael R Klapal,
Michael S Araneta,
Michelle M Noe,
Mihaly S Ligmond,
Mikhail V Ovanesov, PhD,
Nailing Zhang,
Nataniel Phillips Sylvain, PhD,
Patricia Fhughes Troost,
Paul L Bellamy,
Prabhu P Raju,
Qiao Y Bobo,
Rabia Ballica, PhD,
Rachael O Oyewole,
Ramon E Martinez,
Richard Ledwidge (nmi), PhD,
Riley C Myers, PhD,
Riley Meyers,
Robert J Martin,
Russell J Glapion,
S Lori Brown, PhD MPH,
Saleem A Akhtar,
Samuel Mindaye,
Scott C Lute,
Scott Lute,
Tamil Arasu, PhD,
Teegan Dellibovi Ragheb, PhD,
Thomas J Arista,
Thuy T Nguyen, LCDR,
V Teres Speer,
Vanessa Y Gelsey, PhD,
Vanessa Y Jacobs,
Wayne E Seifert,
Wendy G Tan, PhD,
Yan Wang,
Yideng Liang,
Yuan Chia Kuo,
Yvesna C Blaise,
Zhihao Qiu (Peter), PhD,
Zhong Li, PhD
Charles Yuanchia Kuo, PhD's Documents
Publish Date | Document Type | Title |
---|---|---|
July, 2023 | FDA 483 | ImClone Systems LLC - Form 483, 2023-07-27 |
March, 2023 | FDA 483 | Rentschler Biopharma Inc. - Form 483, 2023-03-22 |
March, 2022 | FDA 483 | Shire Human Genetic Therapies, Inc. - Form 483, 2022-03-23 |
February, 2023 | EIR | AGC Biologics, Inc. - EIR, 2023-09-18 |
March, 2023 | FDA 483 | Rentschler Biopharma Inc. - Form 483, 2023-03-22 |
February, 2023 | FDA 483 | AGC Biologics, Inc. - Form 483, 2023-02-10 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more